Home > Insider Trading > Filing (0001209191-14-012240)

Filing Details

Accession Number:: 0001209191-14-012240
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-20 14:50:17
Reporting Period:: 2014-02-18

Filing Date:: 2014-02-20
Accepted Time:: 2014-02-20 14:50:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1419600	Flexion Therapeutics Inc	FLXN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1201580	D Samuel Colella	C/O Flexion Therapeutics, Inc. 10 Mall Road, Suite 301 Burlington MA 01803		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-18	2,405,429	$0.00	2,511,209	No	4	C	Indirect	By entities affiliated with Versant Ventures
Common Stock	Acquisiton	2014-02-18	387,906	$0.00	2,899,115	No	4	C	Indirect	By entities affiliated with Versant Ventures
Common Stock	Acquisiton	2014-02-18	307,692	$13.00	3,206,807	No	4	P	Indirect	By entities affiliated with Versant Ventures

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By entities affiliated with Versant Ventures
No	4	C	Indirect	By entities affiliated with Versant Ventures
No	4	P	Indirect	By entities affiliated with Versant Ventures

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-18	19,556,148	$0.00	2,405,429	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-18	3,153,677	$0.00	387,906	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The shares are held as follows: 2,036,697 by Versant Venture Capital III, L.P., 12,029 by Versant Side Fund III, L.P. and 356,703 by Versant Development Fund III, LLC. The Reporting Person shares voting and investment power with respect to the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The shares are held as follows: 385,629 by Versant Venture Capital III, L.P. and 2,277 by Versant Side Fund III, L.P. The Reporting Person shares voting and investment power with respect to the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
The shares were purchased at the Issuer's initial public offering.
The shares are held as follows: 305,886 by Versant Venture Capital III, L.P. and 1,806 by Versant Side Fund III, L.P. The Reporting Person shares voting and investment power with respect to the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.